What is Oncomatryx?
Oncomatryx is dedicated to advancing the treatment paradigm for challenging metastatic solid tumors. The company's core innovation lies in its Tumor Quantum Immunotherapy, a precision approach designed to modulate the tumor microenvironment. With over a decade of research and development, Oncomatryx's scientific team is committed to creating novel therapeutic agents that address unmet needs in oncology.
How much funding has Oncomatryx raised?
Oncomatryx has raised a total of $54.2M across 3 funding rounds:
Other Financing Round
$16.2M
Other Financing Round
$26M
Other Financing Round
$12M
Other Financing Round (2022): $16.2M, investors not publicly disclosed
Other Financing Round (2025): $26M led by The CDTI
Other Financing Round (2025): $12M supported by The European Innovation Council
Key Investors in Oncomatryx
The CDTI
CDTI is an agency supporting knowledge-based innovation and internationalizing R&D projects for Spanish companies. It manages Spanish participation in international R&D organizations and focuses on the Science and Space industries.
The European Innovation Council
The European Innovation Council operates within the Colleges & Universities sector, supporting innovation and research initiatives.
What's next for Oncomatryx?
The recent major strategic investment signifies a critical juncture for Oncomatryx, likely enabling the company to accelerate its clinical development pipeline and expand its research initiatives. This substantial backing from enterprise-level investors suggests a strategic focus on scaling operations, advancing drug candidates through rigorous trials, and potentially forging key partnerships. The company's trajectory indicates a strong push towards bringing its innovative immunotherapies to patients.
See full Oncomatryx company page
